All Stories
Follow
Subscribe to Davidson Kempner

Davidson Kempner

Davidson Kempner[1] Now Holds an 8.0% Stake and Finds Qiagen's Standalone Prospects Highly Attractive

London (ots/PRNewswire)

Davidson Kempner continues to increase its position and now holds an 8.0% stake. We fully expect the current offer to fail and we view the current price level as a very attractive entry point. We remain confident in Qiagen's prospects and that the standalone value is attractive over both the short and long term.

Davidson Kempner Will Not Be Tendering into the Current Offer

Davidson Kempner sees Qiagen's standalone fair value as EUR48-52/share and therefore considers the current offer wholly inadequate. Davidson Kempner will not be tendering its shares into the current offer. We are encouraged by the recent public statements against the deal by other shareholders and we urge other shareholders to likewise reject the offer.

For media enquiries:
Greenbrook
Andrew Honnor, Rob White, Fanni Bodri
Email: davidsonkempner@greenbrookpr.com
Tel: +44-(0)20-7952-2000

1. Davidson Kempner European Partners, LLP is the sub-adviser to Davidson Kempner Capital Management LP which acts as the discretionary investment manager to various funds which hold in aggregate 8.0% of the share capital of Qiagen N.V. as of 3 August 2020.

Original content of: Davidson Kempner, transmitted by news aktuell

More stories: Davidson Kempner
More stories: Davidson Kempner
  • 31.07.2020 – 15:42

    Davidson Kempner Letter to Qiagen NV

    London (ots/PRNewswire) - To: Dr. Håkan Björklund (Chairman of the Supervisory Board) Stéphane Bancel (Supervisory Board Director) Dr. Metin Colpan (Supervisory Board Director) Prof. Dr. Ross Levine (Supervisory Board Director) Prof. Dr. Elaine Mardis (Supervisory Board Director) Lawrence A. Rosen (Supervisory Board Director and Chairman of the Audit Committe e) Elizabeth E. Tallett (Supervisory Board Director and ...

  • 28.07.2020 – 17:51

    Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN N.V. to Fail

    London (ots/PRNewswire) - 1. Davidson Kempner European Partners, LLP is the sub-adviser to Davidson Kempner Capital Management LP which acts as the discretionary investment manager to various funds which represent 5.1% of the share capital of QIAGEN N.V. (the "Company") 2. Davidson Kempner believes the standalone fair value for the Company to be EUR48-52 per share 3. ...

  • 16.07.2020 – 19:21

    Davidson Kempner Letter to Qiagen NV

    London (ots/PRNewswire) - To: Dr. Håkan Björklund (Chairman of the Supervisory Board) Stéphane Bancel (Supervisory Board Director) Dr. Metin Colpan (Supervisory Board Director) Prof. Dr. Ross Levine (Supervisory Board Director) Prof. Dr. Elaine Mardis (Supervisory Board Director) Lawrence A. Rosen (Supervisory Board Director and Chairman of the Audit Committe e) Elizabeth E. Tallett (Supervisory Board Director and ...